![John Henneman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Henneman
Direktor/Vorstandsmitglied bei
APREA THERAPEUTICS, INC.
Vermögen: 1 Mio $ am 31.05.2026
Profil
John B. Henneman is Lead Independent Director at Anika Therapeutics, Inc. since 2026.
Independent Director at Orthofix Medical, Inc. since 2023.
Director at Alafair Biosciences, Inc. since 2015.
Director at Aprea Therapeutics AB since 2019.
Lead Independent Director at Aprea Therapeutics, Inc. since 2020.
Formerly Interim Co-Chief Executive Officer & Secretary at Neuromedical Systems, Inc. Independent Director at SeaSpine Holdings Corp.
from 2015 to 2023.
Lead Independent Director at R1 RCM, Inc. from 2022 to 2024.
Chief Financial Officer at Integra LifeSciences Holdings Corp.
from 2007 to 2014.
Chief Administrative Officer at NewLink Genetics Corp.
in 2018.
President at New Deal Technology SAS. Education includes an undergraduate degree from Princeton University in 1983 and a graduate degree from The University of Michigan Law School in 1986.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.06.2026 | 65’273 ( 0.49% ) | 948 417 $ | 31.05.2026 | |
| 10.06.2026 | 42’462 ( 0.11% ) | 393 623 $ | 31.05.2026 | |
| 16.06.2026 | 10’229 ( 0.08% ) | 9 134 $ | 31.05.2026 |
Aktive Positionen von John Henneman
| Unternehmen | Position | Beginn |
|---|---|---|
| APREA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.08.2019 |
| ANIKA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.02.2026 |
| ORTHOFIX MEDICAL INC. | Direktor/Vorstandsmitglied | 05.01.2023 |
Alafair Biosciences, Inc.
 Alafair Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops naturally-derived biopolymer technologies to reduce scarring, enhance mobility and accelerate patient recovery | Direktor/Vorstandsmitglied | 01.01.2015 |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Direktor/Vorstandsmitglied | 01.08.2019 |
Ehemalige bekannte Positionen von John Henneman
| Unternehmen | Position | Ende |
|---|---|---|
| R1 RCM INC. | Direktor/Vorstandsmitglied | 19.11.2024 |
| SEAE HLDG | Direktor/Vorstandsmitglied | 05.01.2023 |
| LUMOS PHARMA, INC. | Finanzdirektor/CFO | 26.07.2018 |
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Finanzdirektor/CFO | 01.09.2014 |
| ░░░░░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░ | - |
Ausbildung von John Henneman
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
78
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Integra LifeSciences Holdings Corp.
 Integra LifeSciences Holdings Corp. Medical SpecialtiesHealth Technology Develops, manufactures and markets medical devices, implants and biomaterials | Health Technology |
Anika Therapeutics, Inc.
 Anika Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair | Health Technology |
Neuromedical Systems, Inc.
 Neuromedical Systems, Inc. Medical SpecialtiesHealth Technology Develops, makes and markets a supplemental test to aid laboratories in the detection of abnormal cells | Health Technology |
Orthofix Medical, Inc.
 Orthofix Medical, Inc. Medical SpecialtiesHealth Technology Develops and markets surgical products to the spine & orthopedic markets | Health Technology |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops, and commercializes novel immunotherapeutic products for treatment of cancer | Health Technology |
Alafair Biosciences, Inc.
Alafair Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops naturally-derived biopolymer technologies to reduce scarring, enhance mobility and accelerate patient recovery | Commercial Services |
SeaSpine Holdings Corp.
 SeaSpine Holdings Corp. Medical SpecialtiesHealth Technology Designs, develops and sells surgical solutions for the treatment of patients suffering from spinal disorders | Health Technology |
New Deal Technology SAS
 New Deal Technology SAS Medical SpecialtiesHealth Technology Develops and manufactures specialty implants and instruments for foot and ankle surgery | Health Technology |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Health Technology |
R1 RCM, Inc.
 R1 RCM, Inc. Packaged SoftwareTechnology Services Develops as a healthcare revenue cycle management platform | Technology Services |
The University of Michigan Law School
 The University of Michigan Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aprea Therapeutics, Inc.
 Aprea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel anticancer compounds | Health Technology |
